All Type of News
Kwangdong clinical study approved for KD501, Arzheimer drug.
Kwangdong announced on July 23 that a clinical phase II study protocol for KD501, an Arzheimer disease therapy of natural origin, was approved by the KFDA.
KD501 is a new anti-psychotic drug with natural origin jo...
Healthcare industry rapidly to transform in 10 years.
In 10 years the medical institutions and pharmacies would face a rapid change in a way to be larger and specialized.
MOHW official in charge of the drug policy Choi Hee-joo predicted about the future medical and p...
Lowering health insurance benefits for minor disease will facilitate self-medication
The government plan to reduce health insurance coverage for treatment of minor ailments, which will take effect from this August, is expected to additionally induce people's self-medication patterns, and this will res...
Daewoong to launch anti-obesity drug "NVU" next week.
Daewoong said that the KFDA approved NVU capsule (sibutramine), an anti-obesity drug, on July 16.
Daewoong is planning to market two types of NVU at 8.27mg and 12.55mg from July 23 by placing a marketing campaign u...
Daewoong's CoQ10 VQ to target pharmacy market
The co-enzyme Q10 (CoQ10) segment of the health food industry is emerging as a new battlefield as local food makers are introducing a series of new products.
Recently, Daewoong Pharm are aiming its CoQ10 VQ related...
60.2% of female university students suffer from menstrual pain
The majority of female college students suffer from menstrual pain, and about half of them have received a pain killer twice a month.
According to Daewoong Pharm, 5 million women with child-bearing potential in Kor...
Increased coverage for advanced illnesses
The government will lower health insurance benefits for treatment of minor ailments from this August while increasing coverage for advanced illnesses, the Health Ministry announced on July 18.
In a major overhaul a...
NMC rejects to extend prescriptions written in generic names.
The National Medical Center (NMC) said that the Center would never consider the model program of the prescriptions written in generic drug names to extend more therapies as planned to start from coming Sept.
Super...
SK's "M-vix", an erectile dysfunction therapy, to market in Korea.
Following a serial market launching of the drugs for erectile dysfunction therapy by Pfizer, Lilly, Bayer, Dong-A and CKD, SK Chemical seems to enter this annual 80 billion won of markets (as of 2006) very soon.
T...
ZPK to cut wholesaler margin from next year
The controversy over wholesaler margin will be widening as Zuellig Pharma Korea unveiled its plan to lower its margin for associate wholesalers from 0.5 percent to 0.2 percent in their 2008 contract.
During this ye...
